Objective. Intravenous ketamine has been shown to provide postoperative analgesia in many clinical trials, in particular to reduce opioid consumption. The primary objective of this pilot study is to determine if multiple dosing over a three-day perioperative period with oral ketamine is a safe treatment method for acute pain after amputation surgery.
Methods.
Three consented subjects (age 57-60 years) undergoing elective amputation of the lower extremity were included in the study (Institutional Review Board and Food and Drug Administration Investigational New Drug approved). An analgesic dose of oral ketamine (1.0 mg/kg) was administered one hour before surgery. Eight hours after the preoperative dose, a second dose was given. On the first postoperative day, subjects received oral ketamine (1.0 mg/kg) three times per day; and on the second postoperative day, this dose was reduced to 0.5 mg/kg three times per day. The primary outcome measure was the incidence of adverse events.
Results. No serious and unexpected adverse events occurred; therefore, no subject required a dose reduction. The numerical rating score for postoperative pain of the body part adjacent to the amputation site ranged from 0.5-4.0. Morphine milligram equivalent opioid doses were in the range of 0-17.5 mg on the first postop day and 1.0-4.0 mg on the second postop day.
Conclusions. Our pilot study suggests that oral ketamine is safe to use at 1 mg/kg three times per day, as well as convenient for hospital floor and potential home use. Future studies will determine if the perioperative oral ketamine also reduces the incidence of chronic stump or phantom limb pain.
Introduction
Ketamine is a chemically stable nonopioid with analgesic properties at low doses [1] [2] [3] . Ketamine can be administered by the intravenous (IV) route and provides analgesia via antagonism of the N-Methyl-D-Asparate (NMDA) receptor in the central nervous system. IV ketamine has been shown to provide postoperative analgesia in many clinical trials, in particular to reduce opioid consumption [3] . Severe acute pain has been shown to progress to chronic pain due to central sensitization [4] , and perioperative IV ketamine has been shown in limited studies to decrease the incidence of chronic pain after surgery [5] . However, IV administration of ketamine has limitations as ketamine is considered an anesthetic drug and is therefore not administered in unmonitored locations [6] . Therefore, the use of oral ketamine for management of acute pain after trauma or postoperative surgery is highly desirable. In addition, oral administration would permit the drug to be used in a rehabilitation facility or at home after hospital discharge.
All use of oral ketamine in humans is off-label. Therefore, the investigators applied to the Food and Drug Administration (FDA) for Investigational New Drug (IND) approval, and the study was performed under FDA IND No. 120964 (Asokumar Buvanendran, MD, Principal Investigator). While there have been case reports on the long-term use of oral ketamine, there are only a few published clinical studies [7, 8] . In Bredlau et al. (2013) [7] , 12 children with chronic pain were given oral ketamine (in soda or orange juice), three times daily for 14 days, at doses ranging from 0.25-1.5 mg/ kg/dose. They concluded that "oral ketamine at dosages of 0.25-1 mg/kg/dose appears to be safe when given for 14 days to children with chronic pain."
The working hypothesis of our study is that an oral nonopioid medication can be safely used as an adjunct in postamputation pain control. The primary objective of this pilot study is to determine if multiple dosing over a three-day perioperative period with oral ketamine has minimal side effects.
Methods
This pilot study was approved by the Institutional Review Board (IRB) at Rush University Medical Center, Chicago, Illinois. Consented patients older than age 18 and younger than 89 years undergoing elective amputation of the lower extremity from all causes were included in the study. Written informed consent was obtained. The following exclusion criteria were used: pregnancy; increased intracranial pressure or intraocular pressure; allergy to ketamine; morbid obesity (body mass index > 40 kg/m 2 ); significant comorbidity (American Society of Anesthesiologists physical status classification > 3); inability to communicate with the investigators; history of known or suspected drug or alcohol abuse; impaired liver function; history of hallucinations, delusions, or other psychiatric medical conditions that the investigator feels will prevent assessment of adverse events of the study drug; significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression; exposure to cytochrome P450 3A4 inhibitors or inducers; poorly controlled hypertension.
The initial oral ketamine dose was 2.2 mg/kg, based on earlier analgesic studies of intramuscular ketamine in patients [9, 10] and the bioavailability of ketamine after oral dosing [11, 12] . However, in one subject evaluated prior to the study presented here, that dose produced hallucinations in the few hours after administration, and so the dose was reduced to 1 mg/kg for the pilot study.
Postoperative Day 0
An oral dose of ketamine (1.0 mg/kg) was administered one hour prior to surgery. We used the commercially available generic drug Ketamine HCL injection, USP, 100 mg/mL, intended for IV or intramuscular (IM) administration. The 5-mL vials are manufactured by Hospira (Lake Forest, IL, USA) and contain a preservative to allow multiple dosing. The volume of the study medication that the subject received was calculated based on the subject's body weight. For a 1.0-mg/kg dose and a 100-kg subject, 1.0 mL was added to 8 oz (240 mL) of clear liquid (e.g., 7-Up, Gatorade) preoperatively to mask the bitter taste of ketamine. Subjects were not allowed to drink grapefruit juice on the morning of surgery or while receiving the study drug. They were monitored by the research staff at each dosing, which included one hour prior to surgery, eight hours after the first dose, and at 6 AM, 2 PM, and 10 PM on the two days following amputation. If a subject experienced an adverse event (e.g., hallucinations) from the 1.0-mg/kg preoperative dose of ketamine, then further ketamine dosing was delayed until the following day.
The standard anesthesia practice protocol was followed for all subjects undergoing amputation surgery, with the exception of the restriction on administration of additional ketamine during surgery. Standard protocol for these subjects consisted of a balanced anesthesia technique. Preoperatively, the subjects were administered midazolam in 1-mg boluses for anxiolysis depending on the anesthesia provider's assessment of their anxiety level. Intraoperative medications depended on the need for sedation vs general anesthesia. Two of the three subjects underwent general anesthesia, which consisted of propofol for induction followed by the use of a muscle relaxant to obtain ideal intubating conditions. This was followed by the use of an inhaled anesthetic, sevoflurane, to maintain anesthesia, along with a mixture of oxygen and air. The subjects also had fentanyl titrated according to their vital signs during the procedure. The subjects had their muscle relaxation reversed at the end of the procedure with neostigmine and glycopyrrolate. They were subsequently extubated in the operating room and then taken to the recovery room. The one subject who received sedation for his procedure was maintained on a propofol infusion with fentanyl titrated for pain control. This subject had local anesthetic injected at the operative site by the surgical team.
After Surgery
If no adverse event (Table 1) was noted prior to surgery and the subject's next dose was eight hours after their preoperative dose but not after midnight, a second dose was given. Subjects were monitored by the research staff for adverse events two hours after dosing. If an adverse event occurred and did not resolve by the next morning, then oral ketamine was discontinued.
Postoperative Day 1
Subjects received oral ketamine (1.0 mg/kg) mixed with 8 oz of liquid (e.g., soda, Gatorade) three times per day at 6 AM, 2 PM, and 10 PM and monitored by the research staff for adverse events two hours after dosing. If an adverse event occurred but was resolved within eight hours, the next dose was reduced by 33% (i.e., to 0.67 mg/kg). If a subject experienced an adverse event after the second dose that resolved within eight hours, the third dose was reduced again by 33% (to 0.45 mg/kg).
If this dose reduction protocol did not eliminate adverse events, then oral ketamine was discontinued.
Postoperative Day 2 (Tapering Down Period)
Subjects received oral ketamine at half the previous day' s final dose (i.e., 0.5 mg/kg if no dose reduction was made) in 8 oz of liquid three times per day at 6 AM, 2 PM, and 10 PM. Subjects were monitored by the research staff for adverse events two hours after each dose. On the third day, if there were any adverse events after dosing that resolved within eight hours, the dose was reduced by 33%. If dose reduction did not eliminate adverse events, then the subject was taken out of the study.
During the three-day monitoring period, all subjects received standard of care pain control medication. For severe breakthrough pain, subjects received a morphine 2-mg IV push every three hours as needed. Those who had renal insufficiency or had a creatinine clearance of less than 30 mL/min received a hydromorphone 0.3-mg IV push every three hours as needed. For mild pain (pain score of 1-3), acetaminophen 650 mg was given orally every six hours, and those with moderate (pain score of 4-6) to severe pain (pain score of 7-10) were given hydrocodone-acetaminophen 10-325-mg tablets orally every four hours, as needed. Subjects were discharged from the hospital using standard procedures, which included adequate pain control on oral medications.
End Points
We selected outcome measures that have established reliability and validity in safety studies and in acute and chronic postsurgical pain studies. All outcome measures listed below were obtained preoperatively to determine baseline values.
Primary End Point
Incidence of adverse events (Table 1) . Critical adverse drug reactions that would require discontinuation of the study drug were suicidal thoughts or attempts, cardiac arrhythmia and/or severe hypertension, and anaphylaxis (severe allergic reaction).
Secondary End Points
1) Supplementary opioid use (IV or oral) over the threeday ketamine use period. 2) Acute postoperative pain: numerical rating scale (NRS) rating of postoperative pain (0-10 scale) adjacent to the body part that was amputated at 24 and 48 hours postsurgery (average pain over previous 24 hours).
Ketamine Pharmacokinetics
On postoperative day 1 (POD1), at one and four hours after the first morning dose of ketamine, IV blood samples (6 mL) were taken in plasma collection tubes, they were centrifuged, and plasma samples were stored at -20 C. Frozen samples were sent to NMS Labs, Willow Grove, Pennsylvania, and analyzed for ketamine and norketamine (major metabolite) levels by using a gas chromatography/mass spectrometry assay. The detection limit for this assay is 20 ng/mL for both ketamine and norketamine.
Liver Function Tests
As ketamine is metabolized in the liver, all subjects had a liver function test panel prior to surgery and at one month after surgery. If abnormal at one month, the tests would be repeated until they returned to normal (FDA requirement as part of IND approval).
Statistical Analysis and Sample Size
As this is a phase I pilot study, no sample size estimation was performed. The choice of three subjects was deemed adequate to determine that 1 mg/kg was a well-tolerated oral ketamine dose, prior to a larger FDAapproved clinical trial comparing oral ketamine with oral placebo. Pain NRS scores were averaged over each 24-hour day. 
Results
The demographics of the three subjects in the study are shown in Table 2 . Subjects were in the age range of 57-60 years. Amputations were performed between October 8, 2015, and April 29, 2016. In accordance with the FDA adverse event reporting policy, no serious or unexpected events occurred with the three subjects. No subject required a dose reduction due to an adverse event. Table 3 shows the actual ketamine doses used in the study. Subject 2 was discharged early and, therefore, did not receive any ketamine on POD2. All parameters of the liver function test were within normal range, both preoperatively and at one month postoperation. Table 4 shows the subject NRS rating of postoperative pain adjacent to the body part that was amputated at 24 and 48 hours postsurgery (average pain over 24 hours) for each subject. All NRS scores were in the 0.5-4.0 range. Opioid doses were converted to morphine milligram equivalents. Of note, Subject 1, with a diagnosis of chronic regional pain syndrome (CRPS), had been on high-dose opioids (oxycodone plus fentanyl patch) several years prior to surgery, and so they may be considered an outlier in supplementary opioid use.
Similar to the observations by Bredlau (2013) with oral ketamine [7] , many of the plasma ketamine levels were below the level of detection. However, all norketamine levels were measurable (Table 5 ) and were used for describing the pharmacokinetic profiles. Norketamine levels were high at one hour postdose and declined by four hours.
Discussion
Alternatives to current IV opioid analgesics for pain management are needed by health care providers. Based on its use in other settings, ketamine may have advantages, especially if it can be administered in a simple, predictable, effective, and safe manner (orally). Ketamine in liquid formulation is stable at room temperature, which would allow simple packaging. In the United States, there are about 185,000 amputations of limbs annually [13] . Further, the incidence of phantom limb pain after amputation is 79% at six months [14] . Therefore, a treatment protocol with ketamine that can reduce acute pain after amputation using a nonopioid (oral ketamine) and that can potentially also reduce stump and/or phantom limb pain will be a valuable tool for health care providers.
Ketamine is a noncompetitive NMDA antagonist that blocks glutamate, an excitatory neurotransmitter of nociceptive fibers. In rats, ketamine inhibits windup, an increased sensitivity to repeated acute nociceptive stimulation, at the spinal cord level [15] . This is possibly the mechanism of how ketamine reduces acute pain [16] . For almost 50 years, ketamine has been known to attenuate acute nociceptive pain in humans [9, 10, 17] . Low-dose IV ketamine has been shown in many studies to reduce acute postoperative pain [18] [19] [20] . Ketamine also blocks central sensitization, a prolonged increased sensitivity of glutamate at the NMDA receptor that leads to the development of hyperalgesia and allodynia [21, 22] . IV ketamine infusion over three days postsurgery has been shown in limited studies to decrease the incidence of chronic pain after surgery [5] . Blockade of central sensitization may be the basis by which ketamine acts to prevent acute pain after surgery from developing into a chronic pain syndrome [4] , such as stump pain and/or phantom pain after amputation. Many reviews have concluded that IV ketamine infusion can be used to manage acute postoperative pain [3, 4, 20] . However, IV ketamine infusion is impracticable for postoperative use outside of a hospital setting [6] .
There were no adverse events with a dose of 1 mg/kg oral ketamine. This agrees with the Bredlau study in children in which 1 mg/kg oral ketamine three times a day was well tolerated [7] . The norketamine levels after 1.0 mg/kg oral ketamine are similar to those of previous reports [7, 11, 23] , all of which noted a peak norketamine level at one hour postdose, similar to what we observed. Studies with sublingual or buccal transmucosal administration of ketamine have shown that these routes fail to increase ketamine bioavailability vs oral ketamine [24, 25] . Ketamine as nasal spray is problematic for acute use as the amount of drug is difficult to control using an atomizer [25] .
There were no elevated parameters in the subjects' liver function tests at one month postoperation. A study with high-dose intravenous ketamine, >1,500 mg given over 100 hours, had no initial toxic effect in patients, but when that same dose was repeated 16 days later, three out of six patients had elevated liver enzymes [25] . In our study, the highest total oral ketamine dose that any subject received was 655 mg (over three days), and considering that oral ketamine has a 17% bioavailability [11] , this equates to about a 100-mg intravenous dose.
Future studies with oral ketamine should advise subjects to avoid grapefruit juice for five days prior to surgery and while ketamine is being administered as grapefruit juice can interact with intestinal CYP enzymes [26] .
In conclusion, the absence of adverse events in the three subjects when treated with oral ketamine at 1 mg/ kg in multiple doses over a three-day postoperative period after amputation surgery demonstrates that this protocol is well tolerated by subjects and is a suitable dose for more extensive safety and efficacy studies. However, as our oldest subject was only 60 years old, 1 mg/kg PO may not be applicable in older patients. Future studies will determine if perioperative oral ketamine also reduces the incidence of chronic stump or phantom limb pain. While the pharmacology of chronic postamputation pain is a complex issue and multimodal therapies will ultimately be most successful, early intervention with ketamine may have an important role. 
